We are live on ! Find out more
SGA

Sector Gamma AS Portfolio holdings

AUM $423M
1-Year Est. Return 17.56%
This Fund
S&P 500
This Quarter Est. Return
+14.33%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$439M
AUM Growth
+$35.4M
Cap. Flow
-$9.87M
Cap. Flow %
-2.25%
Top 10 Hldgs %
55.71%
Holding
44
New
3
Increased
22
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$7.92M
2
ELV icon
Elevance Health
ELV
+$7.75M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.12M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.87M
5
BDX icon
Becton Dickinson
BDX
+$4.48M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$9.9M
2
BAX icon
Baxter International
BAX
+$8.69M
3
VTRS icon
Viatris
VTRS
+$6.62M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$6.47M
5
HUM icon
Humana
HUM
+$6.23M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$40.2M 9.17%
745,955
+164,688
+28% +$7.92M
MRK icon
2
Merck
MRK
$315B
$38.3M 8.73%
363,651
+41,151
+13% +$3.86M
MDT icon
3
Medtronic
MDT
$106B
$25.9M 5.9%
269,644
-33,797
-11% -$3.28M
BDX icon
4
Becton Dickinson
BDX
$43.6B
$25.7M 5.86%
132,376
+23,547
+22% +$4.48M
GILD icon
5
Gilead Sciences
GILD
$167B
$21.7M 4.94%
176,414
+29,175
+20% +$3.55M
INCY icon
6
Incyte
INCY
$23.4B
$21.6M 4.93%
218,783
+13,669
+7% +$1.32M
PFE icon
7
Pfizer
PFE
$143B
$21.4M 4.88%
859,539
-392,547
-31% -$9.9M
AMGN icon
8
Amgen
AMGN
$198B
$20M 4.55%
60,956
-500
-0.8% -$159K
BIIB icon
9
Biogen
BIIB
$30.4B
$15M 3.43%
85,475
+10,000
+13% +$1.63M
IONS icon
10
Ionis Pharmaceuticals
IONS
$8.99B
$14.6M 3.34%
184,977
-85,986
-32% -$6.47M
CVS icon
11
CVS Health
CVS
$137B
$14.1M 3.21%
177,599
+21,397
+14% +$1.69M
CAH icon
12
Cardinal Health
CAH
$53.5B
$12.7M 2.9%
61,946
+2,410
+4% +$454K
TMO icon
13
Thermo Fisher Scientific
TMO
$198B
$12.6M 2.86%
21,688
+3,244
+18% +$1.83M
BRKR icon
14
Bruker
BRKR
$8.86B
$12M 2.74%
254,697
+3,788
+2% +$160K
ZBH icon
15
Zimmer Biomet
ZBH
$17.6B
$11.9M 2.72%
132,478
+19,000
+17% +$1.8M
BMRN icon
16
BioMarin Pharmaceuticals
BMRN
$11.5B
$11.8M 2.69%
198,505
+22,653
+13% +$1.23M
ELV icon
17
Elevance Health
ELV
$80.9B
$11.4M 2.6%
32,546
+22,943
+239% +$7.75M
CNC icon
18
Centene
CNC
$32.8B
$10.6M 2.42%
258,109
+44,899
+21% +$1.68M
GEHC icon
19
GE HealthCare
GEHC
$28.7B
$9.38M 2.14%
114,390
+3,000
+3% +$234K
EW icon
20
Edwards Lifesciences
EW
$49.4B
$8.22M 1.87%
96,402
+23,422
+32% +$1.92M
AVTR icon
21
Avantor
AVTR
$7.56B
$7.97M 1.82%
695,403
+218,299
+46% +$2.69M
BIO icon
22
Bio-Rad Laboratories Class A
BIO
$8.15B
$7.2M 1.64%
23,750
+923
+4% +$288K
LH icon
23
Labcorp
LH
$23.2B
$6.78M 1.55%
27,019
+1,049
+4% +$279K
LNTH icon
24
Lantheus
LNTH
$7B
$6.24M 1.42%
93,823
+29,420
+46% +$1.71M
TNDM icon
25
Tandem Diabetes Care
TNDM
$1.17B
$5.87M 1.34%
267,091
-2,451
-0.9% -$44.2K
1
2

Similar funds

AFWM
AMJ Financial Wealth Management Leesburg, Virginia $424M AUM 37.24% 1-Year Est. Return
MP
McDonald Partners Cleveland, Ohio $424M AUM 29.07% 1-Year Est. Return
DS
Dalal Street West Lake Hills, Texas $423M AUM 115.19% 1-Year Est. Return
RS
Retirement Solution Redmond, Washington $423M AUM 16.83% 1-Year Est. Return
DF
Dunhill Financial London, United Kingdom $424M AUM 16.79% 1-Year Est. Return
OGM
OnyxPoint Global Management New York $424M AUM 84.95% 1-Year Est. Return
CPIM
Cypress Point Investment Management Mill Valley, California $424M AUM
MPPLM
Midwest Professional Planners Ltd (MPPL) Wausau, Wisconsin $425M AUM 28.89% 1-Year Est. Return

Sector Gamma AS's Q4 2025 Portfolio in Review

As of Q4 2025, Sector Gamma AS held 44 positions worth $439M, up 8.8% from $403M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sector Gamma AS's Q4 2025 filing shows 3 new, 22 increased, 10 reduced and 8 closed positions. Its largest new stake was Crinetics Pharmaceuticals: 115,000 shares worth $5.35M. The largest sale was Pfizer, an estimated $9.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sector Gamma AS's largest Q4 2025 buy was Crinetics Pharmaceuticals: 115,000 shares worth $5.35M.
  • Sector Gamma AS added most to Bristol-Myers Squibb in Q4 2025, an estimated $7.92M increase.
  • Sector Gamma AS's biggest Q4 2025 reduction was Pfizer, cutting an estimated $9.9M.
  • Sector Gamma AS fully exited Baxter International in Q4 2025, selling an estimated $8.69M.
  • Sector Gamma AS's ten largest holdings make up 56% of its $439M portfolio in Q4 2025.
  • Sector Gamma AS opened 3 new positions and closed 8 in Q4 2025.
  • Sector Gamma AS's portfolio value rose 8.8% quarter-over-quarter to $439M.

Based on Sector Gamma AS's 13F filing for Q4 2025, filed 12 Feb 2026.